GSK Pharma delivered a better-than-expected performance in Q3, largely driven by robust volume growth in the general medicine segment and a continued scale-up in vaccine offtake.
GSK Pharma delivered a better-than-expected performance in Q3, largely driven by robust volume growth in the general medicine segment and a continued scale-up in vaccine offtake.